% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Stahl:268860,
author = {Stahl, Fabian and Evert, Bernd O. and Han, Xinyu and
Breuer, Peter and Wüllner, Ullrich},
title = {{S}pinocerebellar {A}taxia {T}ype 3
{P}athophysiology—{I}mplications for {T}ranslational
{R}esearch and {C}linical {S}tudies},
journal = {International journal of molecular sciences},
volume = {25},
number = {7},
issn = {1422-0067},
address = {Basel},
publisher = {Molecular Diversity Preservation International},
reportid = {DZNE-2024-00359},
pages = {3984},
year = {2024},
abstract = {The spinocerebellar ataxias (SCA) comprise a group of
inherited neurodegenerative diseases. Machado-Joseph Disease
(MJD) or spinocerebellar ataxia 3 (SCA3) is the most common
autosomal dominant form, caused by the expansion of CAG
repeats within the ataxin-3 (ATXN3) gene. This mutation
results in the expression of an abnormal protein containing
long polyglutamine (polyQ) stretches that confers a toxic
gain of function and leads to misfolding and aggregation of
ATXN3 in neurons. As a result of the neurodegenerative
process, SCA3 patients are severely disabled and die
prematurely. Several screening approaches, e.g., druggable
genome-wide and drug library screenings have been performed,
focussing on the reduction in stably overexpressed
ATXN3(polyQ) protein and improvement in the resultant
toxicity. Transgenic overexpression models of toxic ATXN3,
however, missed potential modulators of endogenous ATXN3
regulation. In another approach to identify modifiers of
endogenous ATXN3 expression using a CRISPR/Cas9-modified
SK-N-SH wild-type cell line with a GFP-T2A-luciferase (LUC)
cassette under the control of the endogenous ATXN3 promotor,
four statins were identified as potential activators of
expression. We here provide an overview of the high
throughput screening approaches yet performed to find
compounds or genomic modifiers of ATXN3(polyQ) toxicity in
different SCA3 model organisms and cell lines to ameliorate
and halt SCA3 progression in patients. Furthermore, the
putative role of cholesterol in neurodegenerative diseases
(NDDs) in general and SCA3 in particular is discussed.},
subtyp = {Review Article},
keywords = {Humans / Animals / Machado-Joseph Disease: genetics /
Translational Research, Biomedical / Spinocerebellar
Ataxias: genetics / Translational Science, Biomedical /
Animals, Genetically Modified / ASO (Other) / CRISPR/Cas
(Other) / SREBP (Other) / cholesterol (Other) / clinical
trials (Other) / compound modifier (Other) / genomic
modifier (Other) / high throughput screening (Other) / miRNA
(Other) / spinocerebellar ataxia 3 (SCA3) (Other) /
transcriptional and posttranscriptional regulation (Other)},
cin = {AG Wüllner},
ddc = {540},
cid = {I:(DE-2719)1011302},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38612794},
pmc = {pmc:PMC11012515},
doi = {10.3390/ijms25073984},
url = {https://pub.dzne.de/record/268860},
}